CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
SP-102drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03613662
NCT03613662Phase 2Completed
CompareCT.gov

An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy

Semnur Pharmaceuticals, Inc.·interventional·Posted Aug 3, 2018·Updated Jan 13, 2022

In Brief

A Phase 2 clinical trial evaluating SP-102 for Lumbosacral Radicular Pain. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLumbosacral Radicular Pain
CountriesUnited States
CollaboratorsWorldwide Clinical Trials, Scilex Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 3, 2018
Enrollment StartJul 13, 2018
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.9 years ago

Interventions

SP-102drug

Injection